Amesite Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amesite Inc. (Nasdaq: AMST) on December 21, 2021, reporting events that occurred on December 15, 2021. The filing addresses significant changes in the company's executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Departure of CFO: The Board of Directors authorized the termination of Matthew Kern as Chief Financial Officer, effective December 15, 2021.
- Appointment of CFO: The Board appointed Mark Corrao, age 64, as the new Chief Financial Officer, effective December 15, 2021.
- Compensatory Arrangements: A CFO Agreement was entered into with Mr. Corrao, filed as Exhibit 10.1.
Management Commentary and Background
Mr. Corrao brings extensive experience in public accounting, SEC accounting, and corporate taxation. His recent background includes serving as CFO for Neuropathix, Inc. (since 2012), Brain Scientific, Inc. (2018-2021), and Generex Biotechnology Corporation (2017-2021). He previously founded Strikeforce Technologies, Inc. and held roles at Merrill Lynch and Spear Leeds & Kellogg. The filing states there are no family relationships between Mr. Corrao and other directors or officers.
Investor Verification Checklist
- Review the terms of the new CFO Agreement (Exhibit 10.1) for compensation details and severance provisions.
- Verify the transition plan for financial reporting responsibilities between the outgoing and incoming CFO.
- Confirm the company's current liquidity position in subsequent filings, as this 8-K contains no financial data.
- Monitor future 8-K filings for any additional executive departures or strategic shifts following this leadership change.